C
Camila Ferreira de Souza
Researcher at Henry Ford Health System
Publications - 3
Citations - 242
Camila Ferreira de Souza is an academic researcher from Henry Ford Health System. The author has contributed to research in topics: DNA methylation & Glioma. The author has an hindex of 3, co-authored 3 publications receiving 183 citations. Previous affiliations of Camila Ferreira de Souza include University of São Paulo.
Papers
More filters
Journal ArticleDOI
A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence
Camila Ferreira de Souza,Camila Ferreira de Souza,Thais S. Sabedot,Thais S. Sabedot,Tathiane M. Malta,Tathiane M. Malta,Lindsay Stetson,Olena Morozova,Artem Sokolov,Peter W. Laird,Maciej Wiznerowicz,Maciej Wiznerowicz,Antonio Iavarone,James Snyder,Ana C. deCarvalho,Zachary Sanborn,Kerrie L. McDonald,William A. Friedman,Daniela Pretti da Cunha Tirapelli,Laila M. Poisson,Tom Mikkelsen,Carlos Gilberto Carlotti,Steven N. Kalkanis,Jean C. Zenklusen,Sofie R. Salama,Jill S. Barnholtz-Sloan,Houtan Noushmehr,Houtan Noushmehr +27 more
TL;DR: Intra-subtype heterogeneity among G-CIMP-high primary tumors allowed us to identify predictive biomarkers for assessing the risk of malignant recurrence at early stages of disease and offered possibilities to defy glioblastoma progression.
Journal ArticleDOI
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.
Tali Mazor,Charles Chesnelong,Aleksandr Pankov,Llewellyn E. Jalbert,Chibo Hong,Josie Hayes,Ivan Smirnov,Roxanne Marshall,Camila Ferreira de Souza,Camila Ferreira de Souza,Yaoqing Shen,Pavithra Viswanath,Houtan Noushmehr,Houtan Noushmehr,Sabrina M. Ronen,Steven J.M. Jones,Steven J.M. Jones,Marco A. Marra,Marco A. Marra,J. Gregory Cairncross,Arie Perry,Sarah J. Nelson,Susan M. Chang,Andrew W. Bollen,Annette M. Molinaro,Henrik Bengtsson,Adam B. Olshen,Samuel Weiss,Joanna J. Phillips,H. Artee Luchman,Joseph F. Costello +30 more
TL;DR: It is demonstrated that in a subset of initially IDH 1 mutant gliomas IDH1 is deleted or amplified at recurrence, yielding a higher grade tumor with a reprogrammed epigenome, further suggestive of selection against the heterozygous mutant state as tumors progress.
Posted ContentDOI
Distinct epigenetic shift in a subset of Glioma CpG island methylator phenotype (G-CIMP) during tumor recurrence
Camila Ferreira de Souza,Thais S. Sabedot,Tathiane M. Malta,Lindsay Stetson,Olena Morozova,Artem Sokolov,Peter W. Laird,Maciej Wiznerowicz,Antonio Iavarone,James Snyder,Ana C. deCarvalho,Zachary Sanborn,Kerrie L. McDonald,William A. Friedman,Daniela Pretti da Cunha Tirapelli,Laila M. Poisson,Tom Mikkelsen,Carlos Gilberto Carlotti,Steven N. Kalkanis,Jean C. Zenklusen,Sofie R. Salama,Jill S. Barnholtz-Sloan,Houtan Noushmehr +22 more
TL;DR: A set of candidate biomarker signatures that predict recurrence of G-CIMP-low with clinically relevance on patient outcomes is defined and provides opportunity for refined clinical trial designs and therapeutic targets that limit progression to more aggressive G- CIMp-low phenotype.